News | December 26, 2023
AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
Furthering cell therapy ambition across oncology and autoimmune diseases
Furthering cell therapy ambition across oncology and autoimmune diseases
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Evinova will operate as a separate health-tech business within AstraZeneca
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The collaboration brings a seamless digital experience to more formulators worldwide
Subscribe To Our Newsletter & Stay Updated
